Back | Next |
home / stock / scyx / scyx message board
Subject | By | Source | When |
---|---|---|---|
znewcar1: $SCYX 28% v14,5M c2.00 f32,6M H2.28 ML1.15 | znewcar1 | investorshangout | 03/22/2023 10:41:08 PM |
$SCYX: Hey, THANKS for that link!! WOW!! (I | Invest-in-America | investorshub | 03/22/2023 2:41:01 PM |
Anti-Fungal Stocks Rally Following CDC Fungus Study -- | BooDog | investorshub | 03/22/2023 2:34:29 PM |
znewcar1: $SCYX 36% v3,6M hod2.19 f32,656,992 SCYNEXIS Inc. SCYX Message Board SCYX RSS Feed Establi | znewcar1 | investorshangout | 03/22/2023 2:17:34 PM |
Trimmed a few here 2.08. Looking good though!! | BooDog | investorshub | 03/22/2023 2:13:51 PM |
$SCYX: Running this morn.???? | Invest-in-America | investorshub | 03/22/2023 1:40:20 PM |
1.70's pm | BooDog | investorshub | 03/22/2023 12:37:25 PM |
SCYNEXIS Announces FDA Approval of Second Indication for | BooDog | investorshub | 12/01/2022 2:40:12 PM |
SCYNEXIS, Inc.Novel Anti-Infective Treatments | BooDog | investorshub | 11/21/2022 11:28:49 AM |
Looking better than I thought. See how | BooDog | investorshub | 11/21/2022 11:19:54 AM |
Lol. Out 2.19. Paid for dinner. | BooDog | investorshub | 11/18/2022 6:38:55 PM |
Pushing on up! | BooDog | investorshub | 11/18/2022 5:54:53 PM |
RE: THE WEBLINK BELOW: | GMA13 | investorshub | 04/30/2022 7:36:03 PM |
Today, I emailed Irina of $SCYX - IR | GMA13 | investorshub | 02/07/2022 7:14:23 PM |
$SCYX WebMD has 7 rVVC patient reviews | GMA13 | investorshub | 02/05/2022 7:41:57 PM |
Launch in a few weeks. Reps are being | stox777 | investorshub | 01/25/2022 8:07:38 PM |
znewcar1: SCYX 25% v2,5M c6.75 f23,2M H7.13 | znewcar1 | investorshangout | 11/15/2021 11:28:29 PM |
anyone have any projections for this stock for | 351stang | investorshub | 11/15/2021 8:01:41 PM |
Another chart | conix | investorshub | 06/10/2021 6:25:09 PM |
$SCYX Chart | conix | investorshub | 06/10/2021 6:03:03 PM |
News, Short Squeeze, Breakout and More Instantly...
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata SCY-247 showed in vitro activity ...
In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrata SCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species JERSEY C...
JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to o...